
In the first episode of The Biotech Brief, we break down what Yeztugo is, why it matters, how it compares to daily pills, and what this means for the $45 billion HIV prevention market.
Version: 20241125
In the first episode of The Biotech Brief, we break down what Yeztugo is, why it matters, how it compares to daily pills, and what this means for the $45 billion HIV prevention market.
No comments yet. Be the first to say something!